How chemokines organize the tumour microenvironment

• Published in: Nature reviews. Cancer Vol. 24; no. 1; pp. 28 - 50
• Main Authors: Mempel, Thorsten R., Lill, Julia K., Altenburger, Lukas M.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.01.2024; Nature Publishing Group
• Subjects: 631/250/580; 631/250/98; 631/67/327; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer Research; Cell differentiation; Cell survival; Chemokines; Extravasation; Functional morphology; Hematopoietic stem cells; Homeostasis; Humans; Immune response; Immune System; Immune Tolerance; Immunological tolerance; Neoplasms - pathology; Physiology; Review Article; Solid tumors; Stromal cells; Therapeutic applications; Tumor Microenvironment; Tumors
• ISSN: 1474-175X; 1474-1768; 1474-1768
• DOI: 10.1038/s41568-023-00635-w

For our immune system to contain or eliminate malignant solid tumours, both myeloid and lymphoid haematopoietic cells must not only extravasate from the bloodstream into the tumour tissue but also further migrate to various specialized niches of the tumour microenvironment to functionally interact with each other, with non-haematopoietic stromal cells and, ultimately, with cancer cells. These interactions regulate local immune cell survival, proliferative expansion, differentiation and their execution of pro-tumour or antitumour effector functions, which collectively determine the outcome of spontaneous or therapeutically induced antitumour immune responses. None of these interactions occur randomly but are orchestrated and critically depend on migratory guidance cues provided by chemokines, a large family of chemotactic cytokines, and their receptors. Understanding the functional organization of the tumour immune microenvironment inevitably requires knowledge of the multifaceted roles of chemokines in the recruitment and positioning of its cellular constituents. Gaining such knowledge will not only generate new insights into the mechanisms underlying antitumour immunity or immune tolerance but also inform the development of biomarkers (or ‘biopatterns’) based on spatial tumour tissue analyses, as well as novel strategies to therapeutically engineer immune responses in patients with cancer. Here we will discuss recent observations on the role of chemokines in the tumour microenvironment in the context of our knowledge of their physiological functions in development, homeostasis and antimicrobial responses. In this Review, Mempel et al. use our understanding of the physiological response programmes of the immune system to the more commonplace challenges it encounters as a framework to interpret observations of chemokine function in tumours. When viewed in this way, the design of more effective therapeutic interventions leveraging the chemokine system to recalibrate response patterns to cancer might be possible.